Pulmonary embolism accounts for almost 100,000 deaths each year in India, and recurrence is likely to occur in 30% of patients within ten years in the form of a new embolism. A new class of drugs recently approved by the USFDA, known as PCSK9 inhibitors, lowers LDL levels in the body and prevents heart attacks or strokes. These drugs can effectively prevent the formation of emboli and the associated cardiovascular complications if used appropriately. Therefore, sound knowledge of thrombolytic agents and individualized management plans is essential for improving patient outcomes and preventing the disease from reoccurring.
In this regard, Docplexus has organized an interactive case-based session , where Dr. Hemang Baxi and Dr. Tejas Patel will share their insights on the “Management of Pulmonary Embolism and The Use of PCSK9 Inhibitors for Cardiovascular Patients” on 16 th August…
